CN1544078A - Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy - Google Patents
Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy Download PDFInfo
- Publication number
- CN1544078A CN1544078A CNA2004100444136A CN200410044413A CN1544078A CN 1544078 A CN1544078 A CN 1544078A CN A2004100444136 A CNA2004100444136 A CN A2004100444136A CN 200410044413 A CN200410044413 A CN 200410044413A CN 1544078 A CN1544078 A CN 1544078A
- Authority
- CN
- China
- Prior art keywords
- chemotherapy
- hours
- chinese patent
- tumor
- relative density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 23
- 201000002364 leukopenia Diseases 0.000 title claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 20
- 231100001022 leukopenia Toxicity 0.000 title claims abstract description 20
- 238000001959 radiotherapy Methods 0.000 title abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000009636 Huang Qi Substances 0.000 claims abstract description 20
- 238000010025 steaming Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 20
- 235000008434 ginseng Nutrition 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 17
- 241000222640 Polyporus Species 0.000 claims description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 238000004064 recycling Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 210000000952 spleen Anatomy 0.000 abstract description 12
- 230000036737 immune function Effects 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 5
- 206010013781 dry mouth Diseases 0.000 abstract description 5
- 206010022437 insomnia Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 206010028372 Muscular weakness Diseases 0.000 abstract description 3
- 230000036473 myasthenia Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000001124 body fluid Anatomy 0.000 abstract description 2
- 239000010839 body fluid Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 241000282461 Canis lupus Species 0.000 abstract 1
- 241000735234 Ligustrum Species 0.000 abstract 1
- 240000002624 Mespilus germanica Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000171085 Polyporus umbellatus Species 0.000 abstract 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 238000010411 cooking Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000005946 Xerostomia Diseases 0.000 description 3
- -1 filter Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000030208 low-grade fever Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy and method for making same, which is of desired formulation dosage forms that can be prepared according to the routine process after the effective substances are extracted from red ginseng, Radix Astragali, polyporus umbellatus, poria cocos wolf, medlar, privet (wine steaming) by adopting a process of water cooking and alcohol extracting and are then mixed homogeneously. Compared with the prior art, the present invention possesses the functions of qi benefiting, spleen strengthening, liver and kidney nourishing; is suitable for immune function declines especially leucocytopenia caused by radiotheraphy and chemotherapy, for various tumor patients; exhibits distinct treating effects for patients having the clinical manifestation of deficiency of both qi and yin, such as languishment, lack of appetite, myasthenia of limbs, dry mouth, throat dryness, red tongue and few body fluid; insomnia, and the like; has a simple manufacturing technique, with the product quality being convenient to control, without toxic and side effects.
Description
Technical field: the present invention relates to a kind ofly to be used for the treatment of that tumor is put, the Chinese patent medicine of leukopenia after chemotherapy and preparation method thereof, belong to the field of traditional Chinese medicine technology.
Background technology: radiation and chemotherapy is the effective means of present clinical treatment tumour.But put, chemotherapy can bring bigger toxic and side effects to tumor patient, wherein commonly tumor patient is accepted leukopenia and immunologic function reduction phenomenon to occur after radiotherapy, the chemotherapy, and with dizzy, weak, extremity are aching and limp, parched throat xerostomia, red tongue with a little fluid, inappetence, symptom such as low grade fever, insomnia, thus the considerable part patient can not finish the effective course of treatment and affects the treatment.Therefore, how to alleviate put, the toxicity of chemotherapy, improve the patient immune function, be a need to be resolved hurrily important topic of research of domestic and international medical domain for many years all the time.
Summary of the invention: the objective of the invention is to: provide a kind of and can treat that tumor is put, the Chinese patent medicine of leukopenia after chemotherapy and preparation method thereof; To solve the problem that prior art exists,, be used to instruct suitability for industrialized production for the patient provides the preparation method of a kind of effective treatment with Chinese patent medicine and this Chinese patent medicine preparation; The present invention constitutes like this: calculate according to components by weight percent, it mainly is prepared from by Radix Ginseng Rubra 30-70 part, Radix Astragali 50-150 part, Polyporus 100-200 part, Poria 60-150 part, Fructus Lycii 50-140 part, Fructus Ligustri Lucidi (wine steaming) 50-150 part.Be that it is prepared from by Radix Ginseng Rubra 50g, Radix Astragali 100g, Polyporus 150g, Poria 100g, Fructus Lycii 100g, Fructus Ligustri Lucidi (wine steaming) 100g and appropriate amount of auxiliary materials more accurately.Described preparation comprises the preparation that granule, capsule, tablet, drop pill, oral liquid, injection, slow releasing preparation, controlled release preparation etc. medically allow.
Its preparation method is: adopt the method for decocting in water, alcohol extraction to extract mix homogeneously behind the active substance Radix Ginseng Rubra, the Radix Astragali, Polyporus, Poria, Fructus Lycii, Fructus Ligustri Lucidi (wine steaming), and then be prepared into the preparation formulation that needs according to common process.
Wherein: oral liquid prepares like this: Radix Ginseng Rubra 50g, Radix Astragali 100g, Polyporus 150g, Poria 100g, Fructus Lycii 100g, Fructus Ligustri Lucidi (wine steaming) 100g are decocted with water 3 times, gradation filters, merging filtrate, it is relative density 1.05 that the medicinal liquid that obtains for 3 times is concentrated into 60 ℃ of surveys, cold preservation, filter, stevioside 1.4g is added adding above-mentioned medicinal liquid in dissolving back in the hot water, transfer about PH to 6.0, add water to 1000ml with sodium hydroxide, fill, sterilization promptly.
Granule prepares like this: above 6 flavor medicines decoct with water boil the back keep little and boil, 3 times, 2.5 hours for the first time, 1.5 hours for the second time; 1.0 hours for the third time, gradation filtered, merging filtrate; surveying relative density when being concentrated into 60 ℃ is 1.05; 2 ℃ of cold preservation 48 hours is filtered, and filtrate is put in the one-step-granulating method; add sucrose fine; make granule, packing, promptly.
Capsule prepares like this: get Radix Ginseng Rubra, the Radix Astragali, Fructus Ligustri Lucidi (wine steaming) adds 7 times of amount 80% alcohol reflux 2 times, each 1.5 hours, filters, the survey relative density was 1.15 clear paste when merging filtrate, concentrating under reduced pressure became to 60 ℃, spray drying, the collection fine powder is standby, and other gets all the other 3 flavors such as Fructus Lycii and adds 10 times of water gagings and decoct each 1.5 hours 3 times, filter, the survey relative density was 1.10 clear paste when merging filtrate, concentrating under reduced pressure became to 60 ℃, add an amount of ethanol, to containing the alcohol amount is 70%, leaves standstill 24 hours, filters, when becoming to 60 ℃, filtrate recycling ethanol and concentrating under reduced pressure survey, relative density is 1.15 clear paste, adding an amount of ethanol is 85% to containing the alcohol amount, leaves standstill 24 hours, filters, the survey relative density was 1.20 clear paste when filtrate recycling ethanol and concentrating under reduced pressure became to 60 ℃, add starch, mixing, vacuum drying, be ground into fine powder, with above-mentioned fine powder mixing,, cross 30 mesh sieves with 70% alcohol granulation, 60 ℃ of dryings, granulate, fill, promptly.
Tablet prepares like this: get Radix Ginseng Rubra, the Radix Astragali, Fructus Ligustri Lucidi (wine steaming) adds 7 times of amount 80% alcohol reflux 2 times, each 1.5 hours, filters, the survey relative density was 1.15 clear paste when merging filtrate, concentrating under reduced pressure became to 60 ℃, spray drying, the collection fine powder is standby, and other gets all the other 3 flavors such as Fructus Lycii and adds 10 times of water gagings and decoct each 1.5 hours 3 times, filter, the survey relative density was 1.10 clear paste when merging filtrate, concentrating under reduced pressure became to 60 ℃, adding an amount of ethanol, is 70% to containing the alcohol amount, leaves standstill 24 hours, filter, the survey relative density was 1.15 clear paste when filtrate recycling ethanol and concentrating under reduced pressure became to 60 ℃, and adding an amount of ethanol is 85% to containing the alcohol amount, left standstill 24 hours, and filtered, the survey relative density was 1.20 clear paste when filtrate recycling ethanol and concentrating under reduced pressure became to 60 ℃, add starch, mixing, vacuum drying is ground into fine powder, with above-mentioned fine powder mixing, with 70% alcohol granulation, cross 30 mesh sieves, 60 ℃ of dryings, granulate, add carboxymethyl starch sodium and magnesium stearate, mixing, tabletting, the bag film-coat, promptly.
Compared with prior art, the present invention has the effect of replenishing QI to invigorate the spleen, nourishing the liver and kidney, being suitable for various tumor patients caused immunologic function after accepting radiotherapy, chemotherapy reduces, leukopenia particularly, clinical manifestation is that qi-yin deficiency syndrome person therapeutic effect such as lethargy, inappetence, myasthenia of limbs, xerostomia, parched throat, red tongue with a little fluid, low grade fever, insomnia are obvious, do not have toxic and side effects, and production technology is easy, product quality is convenient to control.
Tumor patient is put, leukopenia after chemotherapy shows qi-yin deficiency syndrome, and its etiology and pathogenesis is dirty in the heart, liver,spleen,kidney etc. when duty, is big with spleen, kidney two dirty passes especially, and two dirty back, the congenital foundations of being respectively are basic places of human righteousness.The asthenia of qi and blood then head loses fosterly, and dizziness, weak etc. is arranged; Insufficiency of the spleen then abdominal distention, asthenia, inappetence, QI and blood day void, water retention; Suffering from a deficiency of the kidney, then functioning of bladder is unfavorable, and evil water retention stays; Painstaking effort are lost few, lack of preservation of spirit, then insomnia.The deficiency of vital energy is defended sun and is lost admittedly, and human body is to exopathogen (virus, antibacterial etc.) irresistance; The spleen kidney loses is good for fortune, and every easily giving birth to wet, and be turbid not descending, so-called " institute of heresy gathers, and its gas must be empty ".So the treatment of this disease is worked as with replenishing QI to invigorate the spleen, nourishing the liver and kidney for wanting.
Medicine of the present invention on basis with Radix Ginseng Rubra, Radix Astragali strongly invigorating primordial QI, compatibility Polyporus, Poria, spleen invigorating invigorating middle warmer, promoting diuresis to eliminate damp pathogen.Because of insufficiency of the spleen discomfort, every easily giving birth to wet, and eliminating dampness by diuresis is turbid descending, then clear its effect of the merit of ginseng, stilbene benefit.Kidney controlling essence storage, essence and blood should benefit should not be let out, so take a tonic or nourishing food to build up one's health essence and blood with Fructus Lycii, Fructus Ligustri Lucidi; The main again water liquid of kidney, evil water should should not stay by row, so join Polyporus, Poria promoting diuresis to eliminate damp pathogen.Point out in " becoming convenient talks " as the Zhang Bingcheng of the Qing Dynasty: " ancients must doublely be rushed down heresy with mending, and it is capable that heresy goes then to mend." so to select Radix Ginseng Rubra, the Radix Astragali for use be principal agent to we, strongly invigorating primordial QI, strengthening the spleen promotes the production of body fluid; Polyporus, Poria are accessory drugs, calm the nerves and nourish heart, spleen invigorating invigorating middle warmer, promoting diuresis to eliminate damp pathogen; Fructus Lycii, Fructus Ligustri Lucidi are adjuvant, nourishing the liver and kidney.All medicines share, and play the effect of replenishing QI to invigorate the spleen, nourishing the liver and kidney altogether.The famous Zhang Jiegu of doctor family has saying of " supporting just long-pending from disappearing ", then is to set out according to this important rule of strengthening vital QI to eliminate pathogenic factors, and what is called is just arrogant, QI-blood circulation is normal, and then lump in the abdomen can disappear.Therefore, we are suitable for various tumor patients caused immunologic function after accepting radiotherapy, chemotherapy and reduce, leukopenia particularly, clinical manifestation is qi-yin deficiency syndrome persons such as lethargy, inappetence, myasthenia of limbs, xerostomia, parched throat, red tongue with a little fluid, low grade fever, insomnia.
Clinical observation and curative effect
Verify of curative effect and the untoward reaction of this medicine according to (bureau of drug policy ﹠ administration of Ministry of Health of the People's Republic of China) " provisions for new drugs approval " objectively with " revision and the supplementary provisions of relevant Chinese medicine part ", observe the curative effect of improving qi-yin deficiency syndrome and improving immunologic function simultaneously malignant lymphoma, pulmonary carcinoma, gastric cancer and the caused leukopenia of breast carcinoma patient chemotherapy.Development and trial employment period are observed case 418 examples altogether, and wherein 309 examples are organized in treatment, matched group 109 examples, between two groups sex, age, the sick kind and the relatively equal zero difference in aspects such as pathology typing, operative treatment rate.
One, case is selected
1, the sick kind: through clinical and pathology clarify a diagnosis malignant lymphoma, pulmonary carcinoma, gastric cancer, patient with breast cancer.
2, Chinese medical discrimination: belong to type of deficiency of both QI and YIN.Its symptom: spiritlessness and weakness, deficiency of QI with disinclination to talk, spontaneous sweating, dysphoria with feverish sensation in the chest palms and soles, dry mouth and throat, cardiopalmus, body of the tongue is light red or red, less fur or no fur, thready and weak pulse.
3, in two weeks the chemotherapeutic treatment history is arranged, the peripheral hemogram leukocyte continues above detection of secondary and is lower than 4 * 10
3/ L does not use any shengbai drug person.(leukopenia is and just controls the patient for the first time).
4, the Karnofsky scoring is more than 40 minutes, and expectation can be finished whole therapists.
5, all be inpatient.
6, age＞18 year old≤70 years old adult patients.
Two, observation index:
1, numeration of leukocyte
2, life quality
3, tcm syndrome
4, body weight
5, the heart, kidney, liver function
6, adverse effect
7, immunologic function-NK cytoactive, T cell subsets
Three, Therapeutic Method: be divided into treatment group and matched group at random
The treatment group: ante cibum, (mouth) took this medicine, and every day three times, each 20ml took for 2 weeks continuously.
Four, observed result: observe 418 examples altogether, wherein 309 examples are organized in treatment, matched group 109 examples.The leukopenia that after this medicine is taken the part patient is caused because of chemotherapy rises to normal range in 2 weeks,
Its effective percentage is 83.82%, with matched group 61.47% relatively there were significant differences, P＜0.05.This medicine can improve qi-yin deficiency syndrome, and spiritlessness and weakness, deficiency of QI with disinclination to talk, dysphoria with feverish sensation in the chest palms and soles are significantly improved, and learns by statistics and handles P＜0.05.In addition, life quality and body weight are significantly improved, the NK cell viability is increased, immunologic function is had the certain protection effect.
Through 309 routine patients are observed, do not find that this medicine has untoward reaction, harmless to the heart, liver, renal function.
Preparation for various dosage forms need be selected different adjuvants for use, and we have made experimental selection:
For oral liquid formulations
Sucrose is selected according to (from mouldability, granule yield, cost)
| The investigation project | Adjuvant | ||
| Sucrose | Soluble starch | Dextrin | |
| Mouldability granule yield (%) cost (unit/bag) | Good 95 1.1 | Good 97 1.6 | Good 96 1.8 |
-6-
For capsule preparations:
Starch select according to (from mouldability, granule repair to the angle, RH)
| The investigation project | Adjuvant | |
| Starch | Dextrin | |
| The mouldability granule repair to the angle (°) RH (%) | Good 36.5 55 | Good 41 63 |
For tablet:
Carboxymethyl starch sodium is selected according to (from plain sheet disintegration)
| The investigation project | Adjuvant | ||
| Blank | Starch | Carboxymethyl starch sodium | |
| Plain sheet disintegration (min) | ????53 | ????45 | ??19 |
From this, the present invention is the most scientific and rational for the selection of adjuvant.
The specific embodiment:
Embodiments of the invention 1: get Radix Ginseng Rubra 50g, Radix Astragali 100g, Polyporus 150g, Poria 100g, Fructus Lycii 100g, Fructus Ligustri Lucidi (wine steaming) 100g decoct with water 3 times, gradation filters, merging filtrate, being concentrated into relative density is 1.05 (60 ℃), cold preservation, filter, the 1.4g stevioside is dissolved the back add above-mentioned medicinal liquid in an amount of hot water, transfer about PH to 6.0, add water to 1000ml with sodium hydroxide, fill, sterilization promptly.Oral, 3 times on the one, a 20ml.
Embodiments of the invention 2: get Radix Ginseng Rubra 30g, Radix Astragali 50g, Polyporus 100g, Poria 60g, Fructus Lycii 50g, Fructus Ligustri Lucidi (wine steaming) 50g decoct with water 3 times; gradation filters; merging filtrate, being concentrated into relative density is 1.10 (60 ℃), cold preservation; filter; filtrate is put in the one-step-granulating method, adds the 70g sucrose fine, makes granule; packing, promptly.Boiled water is taken after mixing it with water, 3 times on the one, one time 1 bag.
Embodiments of the invention 3: get Radix Ginseng Rubra 70g, Radix Astragali 150g, Fructus Ligustri Lucidi (wine steaming) 150g adds alcohol reflux 2 times, merging filtrate, and concentrating under reduced pressure becomes clear paste, spray drying, it is standby to collect fine powder, and other gets Polyporus 200g, Poria 150g, Fructus Lycii 140g decocts with water 3 times, merging filtrate, concentrating under reduced pressure becomes clear paste, adds an amount of ethanol, filter, filtrate recycling ethanol and concentrating under reduced pressure become clear paste, add an amount of ethanol and filter, and filtrate recycling ethanol and concentrating under reduced pressure become clear paste, add 35g starch, vacuum drying is ground into fine powder, with above-mentioned fine powder mixing, with alcohol granulation, sieve drying, granulate, fill, promptly.Oral, 3 times on the one, one time 3.
Embodiments of the invention 4: get Radix Ginseng Rubra 70g, Radix Astragali 50g, Fructus Ligustri Lucidi (wine steaming) 50g adds alcohol reflux 2 times, merging filtrate, and concentrating under reduced pressure becomes clear paste, spray drying, it is standby to collect fine powder, and other gets Fructus Lycii 140g, Polyporus 200g, Poria 60g decocts with water 3 times, merging filtrate, concentrating under reduced pressure becomes clear paste, adds an amount of ethanol, filter, filtrate recycling ethanol and concentrating under reduced pressure become clear paste, add an amount of ethanol, filter, filtrate recycling ethanol and concentrating under reduced pressure become clear paste, add 25g starch, vacuum drying is ground into fine powder, with above-mentioned fine powder mixing, with alcohol granulation, sieve drying, granulate, add 0.8g carboxymethyl starch sodium and 0.4g magnesium stearate, mixing, tabletting, the bag film-coat, promptly.Oral, 3 times on the one, one time 3.
Embodiments of the invention 5: injection is got Radix Ginseng Rubra 70g, Radix Astragali 150g, Polyporus 200g, Poria 150g, Fructus Lycii 140g Fructus Ligustri Lucidi (wine steaming) 150g and is adopted after the method effective component extracting that alcohol extraction or decocting boil, and is processed into ejection preparation.
Claims (8)
1, a kind ofly is used for the treatment of that tumor is put, the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: calculate according to components by weight percent, it mainly is prepared from by Radix Ginseng Rubra 30-70 part, Radix Astragali 50-150 part, Polyporus 100-200 part, Poria 60-150 part, Fructus Lycii 50-140 part, Fructus Ligustri Lucidi (wine steaming) 50-150 part.
2, be used for the treatment of according to claim 1 is described that tumor is put, the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: it is prepared from by Radix Ginseng Rubra 50g, Radix Astragali 100g, Polyporus 150g, Poria 100g, Fructus Lycii 100g, Fructus Ligustri Lucidi (wine steaming) 100g and appropriate amount of auxiliary materials.
3, describedly be used for the treatment of that tumor is put, the Chinese patent medicine of leukopenia after chemotherapy according to claim 1 or 2, it is characterized in that: the preparation of described Chinese patent medicine comprises the preparation that granule, capsule, tablet, drop pill, oral liquid, injection, slow releasing preparation, controlled release preparation etc. medically allow.
4, as claimed in claim 1 or 2ly be used for the treatment of that tumor is put, the preparation method of the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: adopt the method for decocting in water, alcohol extraction to extract mix homogeneously behind the active substance Radix Ginseng Rubra, the Radix Astragali, Polyporus, Poria, Fructus Lycii, Fructus Ligustri Lucidi (wine steaming), and then be prepared into the preparation formulation that needs according to common process.
5, put according to the described tumor that is used for the treatment of of claim 4, the preparation method of the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: oral liquid prepares like this: with Radix Ginseng Rubra 50g, Radix Astragali 100g, Polyporus 150g, Poria 100g, Fructus Lycii 100g, Fructus Ligustri Lucidi (wine steaming) 100g decocts with water 3 times, gradation filters, merging filtrate, it is relative density 1.05 that the medicinal liquid that obtains for 3 times is concentrated into 60 ℃ of surveys, cold preservation, filter, stevioside 1.4g is added adding above-mentioned medicinal liquid in dissolving back in the hot water, transfer about PH to 6.0 with sodium hydroxide, add water to 1000ml, fill, sterilization is promptly.
6, be used for the treatment of according to claim 4 is described that tumor is put, the preparation method of the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: granule prepares like this: above 6 flavor medicines decoct with water boil the back keep little and boil, 3 times, 2.5 hours for the first time; 1.5 hours for the second time, 1.0 hours for the third time, gradation filtered; merging filtrate, surveying relative density when being concentrated into 60 ℃ is 1.05,2 ℃ of cold preservations 48 hours; filter; filtrate is put in the one-step-granulating method, adds sucrose fine, makes granule; packing, promptly.
7, put according to the described tumor that is used for the treatment of of claim 4, the preparation method of the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: capsule prepares like this: get Radix Ginseng Rubra, the Radix Astragali, Fructus Ligustri Lucidi (wine steaming) adds 7 times of amount 80% alcohol reflux 2 times, each 1.5 hours, filter, merging filtrate, the survey relative density was 1.15 clear paste when concentrating under reduced pressure became to 60 ℃, spray drying, the collection fine powder is standby, other gets all the other 3 flavors such as Fructus Lycii and adds 10 times of water gagings and decoct 3 times, each 1.5 hours, filters, merging filtrate, the survey relative density was 1.10 clear paste when concentrating under reduced pressure became to 60 ℃, added an amount of ethanol, was 70% to containing the alcohol amount, left standstill 24 hours, filter, survey when filtrate recycling ethanol and concentrating under reduced pressure become to 60 ℃, relative density is 1.15 clear paste, and adding an amount of ethanol is 85% to containing the alcohol amount, left standstill 24 hours, filter, the survey relative density was 1.20 clear paste when filtrate recycling ethanol and concentrating under reduced pressure became to 60 ℃, added starch, mixing, vacuum drying is ground into fine powder, with above-mentioned fine powder mixing, with 70% alcohol granulation, cross 30 mesh sieves, 60 ℃ of dryings, granulate, fill, promptly.
8, be used for the treatment of according to claim 4 is described that tumor is put, the preparation method of the Chinese patent medicine of leukopenia after chemotherapy, it is characterized in that: tablet prepares like this: get Radix Ginseng Rubra, the Radix Astragali, Fructus Ligustri Lucidi (wine steaming) and add 7 times of amount 80% alcohol reflux 2 times, each 1.5 hours, filter, merging filtrate, the survey relative density was 1.15 clear paste when concentrating under reduced pressure became to 60 ℃, spray drying, the collection fine powder is standby, other gets all the other 3 flavors such as Fructus Lycii and adds 10 times of water gagings and decoct 3 times, each 1.5 hours, filters, merging filtrate
The survey relative density was 1.10 clear paste when concentrating under reduced pressure became to 60 ℃, added an amount of ethanol, was 70% to containing the alcohol amount, left standstill 24 hours, and filtered, the survey relative density was 1.15 clear paste when filtrate recycling ethanol and concentrating under reduced pressure became to 60 ℃, adding an amount of ethanol is 85% to containing the alcohol amount, leaves standstill 24 hours, filters, the survey relative density was 1.20 clear paste when filtrate recycling ethanol and concentrating under reduced pressure became to 60 ℃, added starch, mixing, vacuum drying, be ground into fine powder, with above-mentioned fine powder mixing, with 70% alcohol granulation, cross 30 mesh sieves, 60 ℃ of dryings, granulate adds carboxymethyl starch sodium and magnesium stearate, mixing, tabletting, the bag film-coat, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100444136A CN100484550C (en) | 2003-09-25 | 2004-04-27 | Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy, and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03134611.1 | 2003-09-25 | ||
| CN03134611 | 2003-09-25 | ||
| CNB2004100444136A CN100484550C (en) | 2003-09-25 | 2004-04-27 | Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1544078A true CN1544078A (en) | 2004-11-10 |
| CN100484550C CN100484550C (en) | 2009-05-06 |
Family
ID=34378726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100444136A Expired - Lifetime CN100484550C (en) | 2003-09-25 | 2004-04-27 | Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100484550C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103071057A (en) * | 2013-01-10 | 2013-05-01 | 济南康众医药科技开发有限公司 | Medicine for curing yin deficiency type cancerous fever |
| CN103705637A (en) * | 2013-12-25 | 2014-04-09 | 陕西步长制药有限公司 | Traditional Chinese medicinal composition and preparation method thereof |
| CN104740077A (en) * | 2013-12-25 | 2015-07-01 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating tumor diseases and preparation method thereof |
| CN112244298A (en) * | 2020-11-26 | 2021-01-22 | 上海市肺科医院 | A Ginseng radix Rubri iron folic acid composition for adjuvant chemotherapy of lung tumor and its preparation method |
-
2004
- 2004-04-27 CN CNB2004100444136A patent/CN100484550C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103071057A (en) * | 2013-01-10 | 2013-05-01 | 济南康众医药科技开发有限公司 | Medicine for curing yin deficiency type cancerous fever |
| CN103705637A (en) * | 2013-12-25 | 2014-04-09 | 陕西步长制药有限公司 | Traditional Chinese medicinal composition and preparation method thereof |
| CN104740077A (en) * | 2013-12-25 | 2015-07-01 | 陕西步长制药有限公司 | Traditional Chinese medicine preparation for treating tumor diseases and preparation method thereof |
| CN103705637B (en) * | 2013-12-25 | 2016-05-18 | 陕西步长制药有限公司 | A kind of Chinese medicine composition and preparation method thereof |
| CN104740077B (en) * | 2013-12-25 | 2018-03-23 | 陕西步长制药有限公司 | A kind of Chinese medicine preparation for treating neoplastic disease and preparation method thereof |
| CN112244298A (en) * | 2020-11-26 | 2021-01-22 | 上海市肺科医院 | A Ginseng radix Rubri iron folic acid composition for adjuvant chemotherapy of lung tumor and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100484550C (en) | 2009-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612357B (en) | Chinese traditional medicine composition for treating tumor and preparing method thereof | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN100484550C (en) | Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy, and preparation method thereof | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN101167789B (en) | Tumor recovering capsule and production method thereof | |
| CN1291743C (en) | Traditional Chinese medicine for treating stomach cancer and its preparation technology | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN1879755A (en) | Chinese medicinal composition for preparing tumor-treating medicine | |
| CN102631492B (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN101259180B (en) | Shenshe composition and preparation thereof | |
| CN1424052A (en) | Medicine for treating chronic hepatitis B | |
| CN102631486B (en) | Health care composition | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101642485A (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1284545C (en) | Traditional Chinese medicine compound preparation for treating tumor and method for preparing the same | |
| CN102631394B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631489B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN112933135A (en) | Composition for treating spleen and stomach weakness and application thereof | |
| CN1569213A (en) | Cardiac and cerebral vascular disease treating pharmaceutical composition | |
| CN1297297C (en) | Traditional Chinese medicine composition, its preparation method and application for preparing medicine to treat cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANXI BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BUCHANG MEDICAL SCIENCE + TECHNOLOGY DEVELOPING CO., LTD., XIANYANG CITY Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: Box 123, Shaanxi city of Xianyang province Weiyang Road West Patentee after: Shaanxi Buchang Pharmaceuticals Co.,Ltd. Address before: Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Patentee before: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090506 |